CrossrefInfokarte
Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study
Psoriasis: Targets and Therapy · 2025-06 · Volume 15 · 243-259
DOI: 10.2147/ptt.s526748 ↗Abstract
Kein Abstract verfügbar.
EUVIMED